Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

CNTX - Context Therapeutics Inc. Последние... | Finranks

Home

/

CNTX

C

Context Therapeutics Inc. (CNTX)

NCM – Цена в реальном времени. Валюта: USD

0.47

+0.00 (0.88%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

0.48

+0.01 (2.15%)

До открытия: Aug 13, 2026, 4:19 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027 PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights. “During the second quarter, we advanced our pipeline and reported interim Phase 1a data from CTIM-76 in a limited number of heavily pretreated patients with platinum-resistant ovarian cancer (“PROC”) receiving weekly dosing,” said Martin Lehr, Chief Executive Officer of Context.

Видео

No Data

There is no data to display

Пресс-релизы

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027 PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights. “During the second quarter, we advanced our pipeline and reported interim Phase 1a data from CTIM-76 in a limited number of heavily pretreated patients with platinum-resistant ovarian cancer (“PROC”) receiving weekly dosing,” said Martin Lehr, Chief Executive Officer of Context.